CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用嵌合抗原受体工程化 T 细胞对抗血液系统肿瘤：临床试验进展更新
英文原题：Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.
查看英文原题
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）重定向T细胞已显示治疗B细胞白血病/淋巴瘤的疗效，但由于靶抗原丢失或CAR-T 细胞内在功能衰竭，复发仍较常见。为降低复发风险，研究者正在探索对基本治疗策略进行改进，其中部分方案已进入早期临床研究。改进包括同时靶向多个抗原，或将CAR-T 细胞疗法与免疫检查点抑制剂等其他治疗方式联合。本文评估并讨论这些改良型先进疗法及临床前方法长期控制白血病和淋巴瘤的潜力。
展开英文摘要原文
Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to reduce the risk of relapse, some of them are in early clinical exploration.
These include simultaneous targeting of multiple antigens or combination of CAR T-cell therapy with other treatment modalities such as checkpoint inhibitors. The review evaluates and discusses these modified advanced therapies and pre-clinical approaches with respect to their potential to control leukemia and lymphoma in the long-term.
论文信息
- 作者
- Ormhøj M、Abken H、Hadrup SR
- 第一作者单位
- Department of Health Technology, Technical University of Denmark, Lyngby, Denmark. marorm@dtu.dk.Denmark
- 通讯作者单位
- Department of Health Technology, Technical University of Denmark, Lyngby, Denmark. Sirha@dtu.dk.Denmark
- 文献类型
- 综述
- 期刊
- Cancer immunology, immunotherapy : CII2022 Oct
- 原文标识
- PubMed 35199207 · DOI 10.1007/s00262-022-03163-y
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →